The comparison of Ondansetron and Metoclopramide effect on postoperative nausea and vomiting

Clinical trial of comparison of Ondansetron and Metoclopramide effect on postoperative nausea and vomiting in patients with appendisitis and cholecystitis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201601232954N8

Enrollment

Registered

2017-10-21

Start date

2016-09-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Appendicitis. Condition 2: Cholecystitis. Condition 3: Nausea and vomiting. Acute appendicitis Cholecystitis Nausea and vomiting

Interventions

Intervention 1: Intervention: These patients receive 1 milligram per kg Ondansetron(made in Shahredaru Pharmaceutical Company in Islamic Republic Of Iran) single dose

intravenously. Intervention 2: These patients receive 15 milligram Metoclopramide (made in Osveh Pharmaceutical Company in Islamic Republic Of Iran) single dose

intravenously.

Treatment - Drugs

Intervention: These patients receive 1 milligram per kg Ondansetron(made in Shahredaru Pharmaceutical Company in Islamic Republic Of Iran) single dose

These patients receive 15 milligram Metoclopramide (made in Osveh Pharmaceutical Company in Islamic Republic Of Iran) single dose

Eligibility

Sex/Gender

All

Age

15 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with appendicitis and cholecystitis that needs to surgery; ASA I or II; age between 15 to 70 years old; Patients satisfaction on participation in the study. Exclusion criteria: Systolic blood pressure lower than 90 mmHg; Unstable hemodynamic; Opium addiction; history of uncontrolled diseases (Parkinson, Restlessness syndrome, Epilepsy, GI bleeding, Pheochromocytoma); Recent use of CNS depressant drugs; Recent use of antiemetic drugs; allergy to the drugs used in this study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Nausea severity. Timepoint: 1, 6,12 and 24 hours after surgery. Method of measurement: Visual Analogue Scale.;Number of vomiting. Timepoint: 1, 6,12 and 24 hours after surgery. Method of measurement: Questionnaire.	—

Secondary

Measure	Time frame
Pain severity. Timepoint: 1 hour after surgery to 24 hours. Method of measurement: Visual Analogue Scale.;Need to excessive drugs. Timepoint: 1 hour after surgery to 24 hours. Method of measurement: Observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Mohammad Bagher Sohrabi

Shahroud University of Medical science

mb.sohrabi@yahoo.com; mb.sohrabi@shmu.ac.ir+98 23 3239 5054

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026